CIC
SAGE

Cornercap Investment Counsel’s Sage Therapeutics SAGE Stock Holding History

Cornercap Investment Counsel’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,935
Closed -$119K – 628
2024
Q2 		$119K Sell
10,935
-113
-1% -$1.45K 0.02% 568
2024
Q1 		$207K Hold
11,048
– – 0.03% 560
2023
Q4 		$239K Sell
11,048
-18
-0.2% -$357 0.04% 511
2023
Q3 		$228K Buy
+11,066
New +$320K 0.04% 481
2023
Q2 		– Sell
-4,984
Closed -$209K – 651
2023
Q1 		$209K Buy
+4,984
New +$214K 0.04% 499

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cornercap Investment Counsel's SAGE Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 10,935 shares — an estimated $119K sold.

Cornercap Investment Counsel first reported a position in SAGE in Q1 2023 and held it in 5 quarters. The position peaked at $239K in Q4 2023. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 10,935 Sage Therapeutics shares in Q3 2024, an estimated $119K.
  • Cornercap Investment Counsel first reported a position in Sage Therapeutics in Q1 2023 and held it in 5 quarters.
  • Cornercap Investment Counsel's Sage Therapeutics position peaked at $239K in Q4 2023.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.